Skip to nav Skip to content
  • Cancer Type: Genitourinary
  • Study Type: Other
  • NCT#: NCT05874921
  • Phase: N/A
Learn More
  • Overview

    Study Title:

    uTRACT Jelmyto® Registry


    The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.


    Objectives: Primary objectives: The primary objective of the registry is to study the use and impact of Jelmyto in patients with UTUC in clinical practice in the U.S. Secondary objectives: The secondary objectives of the registry are to assess the efficacy, outcomes, and safety of Jelmyto use in sub-groups of clinical interest such as by tumor pathology and location, volume of disease at treatment, renal function at baseline including patients with solitary kidney, route of administration, and history of prior ureteral stenosis.

  • Inclusion Criteria

    • Diagnosis of UTUC
    • Meet at least one of the following criteria:
    • 1. Have been treated with Jelmyto after April 2020
    • 2. Currently undergoing treatment with Jelmyto
    • 3. Will receive Jelmyto
  • Exclusion Criteria

    If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

    Clinical Trial Search